Skip to main content
SpringerLink
Log in

Adverse Effects of NSAIDs in the Gastrointestinal Tract: Risk Factors of Gastrointestinal Toxicity with NSAIDs

  • Chapter
  • First Online:
NSAIDs and Aspirin

  • 2403 Accesses

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) belong to a class of drugs that has potent analgesic and anti-inflammatory effects. They act mainly by inhibiting cyclooxygenase (COX) enzymes including COX-1 and COX-2, which are involved in prostaglandin synthesis. This class of medications includes the traditional, non-selective NSAIDs that inhibit both COX-1 and COX-2, and the newer selective COX-2 inhibitors. They are highly effective in treating various painful conditions such as osteoarthritis and dysmenorrhoea. Unlike other NSAIDs, aspirin is used primarily for its anti-platelet effect to reduce cardiothrombotic risks.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ. 2013;346:f3195. Epub 2013/06/13.

    PubMed  Google Scholar 

  2. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124(2):288–92. Epub 2003/01/31.

    Article  CAS  PubMed  Google Scholar 

  3. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3(1):55–9. Epub 2005/01/13.

    Article  PubMed  Google Scholar 

  4. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000;7(2):115–21. Epub 2001/04/25.

    Article  CAS  PubMed  Google Scholar 

  5. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol. 2006;101(9):2128–38. Epub 2006/07/20.

    Article  PubMed  Google Scholar 

  6. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med. 2001;110(1A):4S–7S. Epub 2001/02/13.

    Article  CAS  PubMed  Google Scholar 

  7. Lassen A, Hallas J. Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. Am J Gastroenterol. 2006;101(5):945–53. Epub 2006/04/01.

    Article  PubMed  Google Scholar 

  8. Taha AS, Angerson WJ, Prasad R, McCloskey C, Blatchford O. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther. 2007;26(8):1171–8. Epub 2007/09/27.

    Article  CAS  PubMed  Google Scholar 

  9. Ishikawa S, Inaba T, Mizuno M, Miyake Y, Okada H, Ishikawa H, et al. Characteristics of serious complicated gastroduodenal ulcers in Japan. Hepatogastroenterology. 2012;59(113):147–54. Epub 2012/01/19.

    PubMed  Google Scholar 

  10. Taha AS, Angerson WJ, Prasad R, McCloskey C, Gilmour D, Morran CG. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;28(7):878–85. Epub 2008/07/23.

    CAS  PubMed  Google Scholar 

  11. Lanas A, Sopena F. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin North Am. 2009;38(2):333–52. Epub 2009/05/19.

    Article  PubMed  Google Scholar 

  12. Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104(7):1633–41. Epub 2009/07/04.

    Article  PubMed  Google Scholar 

  13. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41–60. Epub 2008/06/14.

    Article  CAS  PubMed  Google Scholar 

  14. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888–99. Epub 1999/06/17.

    Article  CAS  PubMed  Google Scholar 

  15. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997;49:15–9. Epub 1997/07/01.

    CAS  PubMed  Google Scholar 

  16. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med. 1989;86(4):449–58. Epub 1989/04/01.

    Article  CAS  PubMed  Google Scholar 

  17. Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med. 1995;1(2):154–8. Epub 1995/02/01.

    Article  CAS  PubMed  Google Scholar 

  18. Lichtenberger LM, Zhou Y, Jayaraman V, Doyen JR, O'Neil RG, Dial EJ, et al. Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine. Biochim Biophys Acta. 2012;1821(7):994–1002. Epub 2012/04/24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hampton DD, Hale LP. Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam. PLoS One. 2011;6(8), e23669. Epub 2011/08/23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology. 1997;112(1):109–17. Epub 1997/01/01.

    Article  CAS  PubMed  Google Scholar 

  21. Somasundaram S, Sigthorsson G, Simpson RJ, Watts J, Jacob M, Tavares IA, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther. 2000;14(5):639–50. Epub 2000/05/03.

    Article  CAS  PubMed  Google Scholar 

  22. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19(12):1861–76. Epub 2013/04/10.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins. 1977;14(2):333–41. Epub 1977/08/01.

    Article  CAS  PubMed  Google Scholar 

  24. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol. 1996;40(8):553–60. Epub 1996/01/01.

    Article  CAS  PubMed  Google Scholar 

  25. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312(7046):1563–6. Epub 1996/06/22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093–9. Epub 2000/07/25.

    Article  CAS  PubMed  Google Scholar 

  27. Masclee GM, Valkhoff VE, Coloma PM, de Ridder M, Romio S, Schuemie MJ, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784-92 e9; quiz e13-4. Epub 2014/06/18.

    Google Scholar 

  28. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79. Epub 2013/06/04.

    Article  CAS  PubMed  Google Scholar 

  29. Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med. 2006;38(6):415–28. Epub 2006/09/30.

    Article  CAS  PubMed  Google Scholar 

  30. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520–8. Epub 2000/11/23.

    Google Scholar 

  31. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002;29(4):804–12. Epub 2002/04/13.

    CAS  PubMed  Google Scholar 

  32. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241–9. Epub 1995/08/15.

    Article  CAS  PubMed  Google Scholar 

  33. Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6):1592–601. Epub 2010/02/24.

    Article  PubMed  CAS  Google Scholar 

  34. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006;24(5):751–67. Epub 2006/08/22.

    Article  CAS  PubMed  Google Scholar 

  35. Yeomans ND. The ulcer sleuths: The search for the cause of peptic ulcers. J Gastroenterol Hepatol. 2011;26 Suppl 1:35–41. Epub 2011/01/14.

    Article  PubMed  Google Scholar 

  36. Wilcox CM, Alexander LN, Cotsonis GA, Clark WS. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci. 1997;42(5):990–7. Epub 1997/05/01.

    Article  CAS  PubMed  Google Scholar 

  37. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009;44(9):879–88. Epub 2009/07/02.

    Article  PubMed  Google Scholar 

  38. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128(5):1172–8. Epub 2005/05/12.

    Article  PubMed  Google Scholar 

  39. Matsumoto T, Kudo T, Esaki M, Yano T, Yamamoto H, Sakamoto C, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol. 2008;43(4):490–6. Epub 2008/03/28.

    Article  CAS  PubMed  Google Scholar 

  40. Watari I, Oka S, Tanaka S, Igawa A, Nakano M, Aoyama T, et al. Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs: a capsule endoscopy study. Digestion. 2014;89(3):225–31. Epub 2014/05/28.

    Article  CAS  PubMed  Google Scholar 

  41. Hall RI, Petty AH, Cobden I, Lendrum R. Enteritis and colitis associated with mefenamic acid. Br Med J (Clin Res Ed). 1983;287(6400):1182. Epub 1983/10/22.

    Google Scholar 

  42. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology. 1992;103(3):862–9. Epub 1992/09/01.

    Article  CAS  PubMed  Google Scholar 

  43. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 1997;112(3):683–9. Epub 1997/03/01.

    Article  CAS  PubMed  Google Scholar 

  44. Smith JA, Pineau BC. Endoscopic therapy of NSAID-induced colonic diaphragm disease: two cases and a review of published reports. Gastrointest Endosc. 2000;52(1):120–5. Epub 2000/07/07.

    Article  CAS  PubMed  Google Scholar 

  45. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–9. Epub 2010/07/20.

    Article  CAS  PubMed  Google Scholar 

  46. Chan FK, Cryer B, Goldstein JL, Lanas A, Peura DA, Scheiman JM, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol. 2010;37(1):167–74. Epub 2009/11/04.

    Article  CAS  PubMed  Google Scholar 

  47. Brun J, Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med. 2001;110(1A):12S–3S. Epub 2001/02/13.

    Article  CAS  PubMed  Google Scholar 

  48. Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012;156(1):69–75. Epub 2010/11/26.

    Article  PubMed  Google Scholar 

  49. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28(5):527–32. Epub 1987/05/01.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis Ann Intern Med. 1991;115(10):787–96. Epub 1991/11/15.

    Article  CAS  PubMed  Google Scholar 

  51. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343(8900):769–72. Epub 1994/03/26.

    Article  CAS  PubMed  Google Scholar 

  52. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114(4):257–63. Epub 1991/02/15.

    Article  CAS  PubMed  Google Scholar 

  53. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343(8905):1075–8. Epub 1994/04/30.

    Article  CAS  PubMed  Google Scholar 

  54. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359(9300):14–22. Epub 2002/01/26.

    Article  CAS  PubMed  Google Scholar 

  55. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38. Epub 2009/02/26.

    Article  PubMed  Google Scholar 

  56. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med. 1996;101(1A):25S–32S. Epub 1996/07/31.

    Article  CAS  PubMed  Google Scholar 

  57. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1995;90(2):206–10. Epub 1995/02/01.

    CAS  PubMed  Google Scholar 

  58. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310(6983):827–30. Epub 1995/04/01.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153(14):1665–70. Epub 1993/07/26.

    Article  CAS  PubMed  Google Scholar 

  60. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864–6. Epub 2012/03/02.

    Article  CAS  PubMed  Google Scholar 

  61. Sipahi I, Celik S, Tozun N. A comparison of results of the US Food and Drug Administration’s mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med. 2014;174(1):150–1. Epub 2013/11/20.

    Article  PubMed  Google Scholar 

  62. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272–4. Epub 2013/03/15.

    Article  CAS  PubMed  Google Scholar 

  63. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145(1):105–12. Epub 2013/03/09.

    Article  CAS  PubMed  Google Scholar 

  64. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24. Epub 2014/11/05.

    Article  PubMed  Google Scholar 

  65. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857. Epub 2015/04/26.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015;350:h1585. Epub 2015/04/26.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Rockey DC. Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants. Nat Rev Gastroenterol Hepatol. 2015;12(3):131–2. Epub 2015/01/21.

    Article  CAS  PubMed  Google Scholar 

  68. Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med. 1976;294(9):473–9. Epub 1976/02/26.

    Article  CAS  PubMed  Google Scholar 

  69. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236(6):619–32. Epub 1994/12/01.

    Article  CAS  PubMed  Google Scholar 

  70. Messer J, Reitman D, Sacks HS, Smith Jr H, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med. 1983;309(1):21–4. Epub 1983/07/07.

    Article  CAS  PubMed  Google Scholar 

  71. Kremer D, Fraser R, Brown JJ, Lever AF, Davies DL, Robertson JI. Amiloride in primary hyperaldosteronism with chronic peptic ulceration. Br Med J. 1973;2(5860):216–7. Epub 1973/04/28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Weil J, Langman MJ, Wainwright P, Lawson DH, Rawlins M, Logan RF, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut. 2000;46(1):27–31. Epub 1999/12/22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123(10):1108–15. Epub 2011/03/02.

    Article  CAS  PubMed  Google Scholar 

  74. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735–40. Epub 1991/05/01.

    Article  CAS  PubMed  Google Scholar 

  75. Curtis JR, Lanas A, John A, Johnson DA, Schulman KL. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(12):1819–28. Epub 2012/06/26.

    Article  Google Scholar 

  76. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007;369(9560):465–73. Epub 2007/02/13.

    Article  CAS  PubMed  Google Scholar 

  77. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21(12):1411–8. Epub 2005/06/14.

    Article  CAS  PubMed  Google Scholar 

  78. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350(9083):975–9. Epub 1997/11/05.

    Article  CAS  PubMed  Google Scholar 

  79. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359(9300):9–13. Epub 2002/01/26.

    Article  CAS  PubMed  Google Scholar 

  80. Leung Ki EL, Chan FK. Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. Best Pract Res Clin Gastroenterol. 2012;26(2):163–72. Epub 2012/05/01.

    Article  CAS  PubMed  Google Scholar 

  81. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344(13):967–73. Epub 2001/03/29.

    Article  CAS  PubMed  Google Scholar 

  82. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144(3):528–35. Epub 2013/01/22.

    Article  CAS  PubMed  Google Scholar 

  83. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352(3):238–44. Epub 2005/01/22.

    Article  CAS  PubMed  Google Scholar 

  84. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347(26):2104–10. Epub 2002/12/27.

    Article  CAS  PubMed  Google Scholar 

  85. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA. 2000;284(10):1247–55. Epub 2000/09/09.

    CAS  PubMed  Google Scholar 

  86. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4, CD002296. Epub 2003/01/10.

    PubMed  Google Scholar 

  87. Rostom A, Muir K, Dube C, Jolicoeur E, Boucher M, Joyce J, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818–28, 28 e1–5; quiz 768. Epub 2007/06/09.

    Google Scholar 

  88. Hudson N, Taha AS, Russell RI, Trye P, Cottrell J, Mann SG, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997;112(6):1817–22. Epub 1997/06/01.

    Article  CAS  PubMed  Google Scholar 

  89. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334(22):1435–9. Epub 1996/05/30.

    Article  CAS  PubMed  Google Scholar 

  90. Simon TJ, Berenson MM, Berlin RG, Snapinn S, Cagliola A. Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. Aliment Pharmacol Ther. 1994;8(1):71–9. Epub 1994/02/01.

    Article  CAS  PubMed  Google Scholar 

  91. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329(7472):948. Epub 2004/10/12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9684):119–25. Epub 2009/07/07.

    Article  CAS  PubMed  Google Scholar 

  93. Chan FK, Sung JJ, Ching JY, Wu JC, Lee YT, Leung WK, et al. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2001;15(1):19–24. Epub 2001/01/03.

    Article  CAS  PubMed  Google Scholar 

  94. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123(5):344–50. Epub 1995/09/01.

    Article  CAS  PubMed  Google Scholar 

  95. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2000;4, CD002296. Epub 2000/10/18.

    PubMed  Google Scholar 

  96. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91(2):223–7. Epub 1996/02/01.

    CAS  PubMed  Google Scholar 

  97. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338(11):719–26. Epub 1998/03/12.

    Article  CAS  PubMed  Google Scholar 

  98. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338(11):727–34. Epub 1998/03/12.

    Article  CAS  PubMed  Google Scholar 

  99. Goldstein JL, Johanson JF, Suchower LJ, Brown KA. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol. 2005;100(12):2650–7. Epub 2006/01/06.

    Article  CAS  PubMed  Google Scholar 

  100. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162(2):169–75. Epub 2002/02/13.

    Article  CAS  PubMed  Google Scholar 

  101. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101(4):701–10. Epub 2006/02/24.

    Article  CAS  PubMed  Google Scholar 

  102. Regula J, Butruk E, Dekkers CP, de Boer SY, Raps D, Simon L, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol. 2006;101(8):1747–55. Epub 2006/07/05.

    Article  CAS  PubMed  Google Scholar 

  103. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bujanda L, Gomollon F, Forne M, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102(3):507–15. Epub 2007/03/07.

    Article  CAS  PubMed  Google Scholar 

  104. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB. Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci. 1994;39(2):362–5. Epub 1994/02/01.

    Article  CAS  PubMed  Google Scholar 

  105. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am. 2010;39(3):433–64. Epub 2010/10/19.

    Article  PubMed  Google Scholar 

  106. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3(2):133–41. Epub 2005/02/11.

    Article  PubMed  Google Scholar 

  107. Goldstein JL, Johanson JF, Hawkey CJ, Suchower LJ, Brown KA. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther. 2007;26(8):1101–11. Epub 2007/09/27.

    Article  CAS  PubMed  Google Scholar 

  108. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141(4):1314–22. Epub 2011/07/13.

    Google Scholar 

  109. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364(9435):665–74. Epub 2004/08/25.

    Article  CAS  PubMed  Google Scholar 

  110. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369(9573):1621–6. Epub 2007/05/15.

    Article  CAS  PubMed  Google Scholar 

  111. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127(2):395–402. Epub 2004/08/10.

    Article  CAS  PubMed  Google Scholar 

  112. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771–81. Epub 2006/11/23.

    Article  CAS  PubMed  Google Scholar 

  113. Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther. 2006;23(10):1489–98. Epub 2006/05/04.

    Article  CAS  PubMed  Google Scholar 

  114. Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford). 2007;46(2):265–72. Epub 2006/07/18.

    Article  CAS  Google Scholar 

  115. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–9. Epub 2004/12/08.

    Article  CAS  PubMed  Google Scholar 

  116. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081–91. Epub 2005/02/17.

    Article  CAS  PubMed  Google Scholar 

  117. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–102. Epub 2005/02/17.

    Article  CAS  PubMed  Google Scholar 

  118. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117(16):2104–13. Epub 2008/04/02.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008;101(7):1060–3. Epub 2008/03/25.

    Article  CAS  PubMed  Google Scholar 

  120. Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006;80(3):264–74. Epub 2006/09/06.

    Article  CAS  PubMed  Google Scholar 

  121. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–8. Epub 2006/06/03.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633–44. Epub 2006/09/14.

    Article  CAS  PubMed  Google Scholar 

  123. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109(12):1468–71. Epub 2004/03/24.

    Article  CAS  PubMed  Google Scholar 

  124. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388–91. Epub 2002/07/18.

    Article  PubMed  Google Scholar 

  125. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361(9357):573–4. Epub 2003/02/25.

    Article  CAS  PubMed  Google Scholar 

  126. FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet. 2003;361(9357):542–4. Epub 2003/02/25.

    Article  PubMed  Google Scholar 

  127. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–17. Epub 2001/12/26.

    Article  CAS  PubMed  Google Scholar 

  128. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007;370(9605):2138–51. Epub 2007/12/25.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Science, and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong, China

    Sunny H. Wong M.B.Ch.B. (Hons.), D.Phil. & Francis K. L. Chan M.D., D.Sc.

Authors
  1. Sunny H. Wong M.B.Ch.B. (Hons.), D.Phil.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francis K. L. Chan M.D., D.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francis K. L. Chan M.D., D.Sc. .

Editor information

Editors and Affiliations

  1. IIS Aragón, CIBER Enfermedades Hepáicas y Digestivas (CIBERehd), Universidad de Zaragoza, Zaragoza, Spain

    Angel Lanas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Wong, S.H., Chan, F.K.L. (2016). Adverse Effects of NSAIDs in the Gastrointestinal Tract: Risk Factors of Gastrointestinal Toxicity with NSAIDs. In: Lanas, A. (eds) NSAIDs and Aspirin. Springer, Cham. https://doi.org/10.1007/978-3-319-33889-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33889-7_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33887-3

  • Online ISBN: 978-3-319-33889-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation